Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AA3P
|
|||
| Drug Name |
PMID29649907-Compound-8
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
INTERCEPT PHARMACEUTICALS, INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Farnesoid X-activated receptor (FXR) | Target Info | Agonist | [1] |
| G-protein coupled bile acid receptor 1 (GPBAR1) | Target Info | Agonist | [1] | |
| Target's Patent Info | Farnesoid X-activated receptor (FXR) | Target's Patent Info | [1] | |
| G-protein coupled bile acid receptor 1 (GPBAR1) | Target's Patent Info | [1] | ||
| KEGG Pathway | Bile secretion | |||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Recycling of bile acids and salts | |||
| PPARA activates gene expression | ||||
| Endogenous sterols | ||||
| Class A/1 (Rhodopsin-like receptors) | ||||
| G alpha (s) signalling events | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Nuclear Receptors Meta-Pathway | ||||
| Farnesoid X Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.